Aprogen Biologics Inc. (KRX:003060)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,738.00
-62.00 (-3.44%)
Sep 1, 2026, 3:30 PM KST

Aprogen Biologics Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
86,18173,22667,37887,36465,19056,482
Revenue Growth
26.13%8.68%-22.88%34.01%15.42%5.93%
Gross Profit
-23,811-27,354-7,846-11,97425,81024,875
Operating Income
-97,909-122,889-58,577-70,690-4,204-3,975
Net Income
-78,296-170,331-104,979-118,27012,6398,103
Earnings Per Share
-5853.51-12931.73-12525.00-28125.004650.003000.00
EPS Growth
----55.00%-42.86%

Revenue by Segment

Fiscal YearFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Dec '24 Dec '23 Dec '22 Dec '21
Pharmaceutical Business Division
57,18657,57162,95464,74355,744
Bio Business Division
5,5759,44816,870274.43-
Semiconductor Business Division
9,636----
Other Sales
829.33358.95812.16--
Total
73,22667,37887,36465,19056,482

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
22,69851,63338,31910,05399,074124,935
Total Debt
210,838228,796154,017180,997134,7382,481
Net Cash (Debt)
-188,139-177,163-115,698-170,944-35,664122,454
Net Cash Growth
------39.41%
Net Cash Per Share
-14065.58-13450.44-13796.70-40646.99-13234.7846085.02

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-32,320-38,233-30,996-33,65125,728-6,227
Capital Expenditures
-3,817-9,625-15,264-28,088-1,284-796.19
Free Cash Flow
-36,137-47,857-46,261-61,73924,444-7,023
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-27.63%-37.35%-11.64%-13.71%39.59%44.04%
Operating Margin
-113.61%-167.82%-86.94%-80.92%-6.45%-7.04%
Pretax Margin
-85.46%-231.31%-155.81%-129.78%22.83%17.41%
Profit Margin
-90.85%-232.61%-155.81%-135.38%19.39%14.34%
FCF Margin
-41.93%-65.36%-68.66%-70.67%37.50%-12.43%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----15.8644.52
P/FCF Ratio
----8.20-
PS Ratio
0.491.401.942.183.086.39